Physician profile
Anna Gramling
NPI 1508033408
$12,104.21
in general payments reported to CMS, 2019-2025
26 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,123 · 2020: $1,693 · 2021: $1,837 · 2022: $2,297 · 2023: $1,559 · 2024: $2,434 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,099 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,099.37 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,075.90 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Abbvie INC. | $2,295.39 | 2019-2025 | |
| Pfizer INC. | $1,440.82 | 2019-2025 | |
| Janssen Biotech, INC. | $1,013.58 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $994.04 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $599.88 | 2019-2024 | Orencia |
| Ucb, INC. | $499.30 | 2019-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals Lp | $430.97 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $425.86 | 2019-2025 | Taltz |
| Horizon Therapeutics Plc | $216.98 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $194.13 | 2019-2025 | Actemra |
| Genzyme Corporation | $173.98 | 2023-2025 | |
| Glaxosmithkline, LLC. | $168.89 | 2019-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $158.86 | 2022-2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $73.25 | 2022-2025 | Strensiq, Ultomiris |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $65.10 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $63.66 | 2019-2020 | |
| Celgene Corporation | $45.32 | 2019 | |
| Mallinckrodt Hospital Products INC. | $37.67 | 2024 | Acthar |
| Argenx US, INC. | $25.69 | 2024 | Vyvgart |
| Sanofi-Aventis U.S. LLC | $21.13 | 2020 | |
| Radius Health, INC. | $19.35 | 2020 | |
| Aurinia Pharma U.S., INC. | $18.70 | 2023 | Lupkynis |
| Scilex Pharmaceuticals INC. | $18.02 | 2024 | |
| Biocon Biologics INC | $14.66 | 2024 | Hulio |
| Kowa Pharmaceuticals America, INC. | $13.08 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Gramling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.